View Financial Healthgenedrive 配当と自社株買い配当金 基準チェック /06genedrive配当金を支払った記録がありません。主要情報n/a配当利回り-13.3%バイバック利回り総株主利回り-13.3%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesGenedrive plc Announces Nhs England Commercial Strategy for Rapid Mt-Rnr1 TestingApr 23genedrive plc has completed a Follow-on Equity Offering in the amount of £0.909643 million.Mar 09genedrive plc has completed a Follow-on Equity Offering in the amount of £0.5 million.Feb 14+ 2 more updatesgenedrive plc, Annual General Meeting, Dec 31, 2025Dec 09genedrive plc to Report Fiscal Year 2025 Results on Dec 05, 2025Dec 03genedrive plc Announces Pilot Programme Study Results Underpinning Nhs Implementation Guide for Cyp2c19 Genotype Testing Presented At the Uk Stroke ForumDec 02Genedrive plc Announces Nhs Implementation Guide Published for Cyp2c19 Genotype TestingNov 27genedrive plc Announces Scotland National Roll-Out of Genedrive MT-RNR1 ID KitNov 26genedrive plc has completed a Follow-on Equity Offering in the amount of £3.1975 million.Sep 25+ 1 more updategenedrive plc has filed a Follow-on Equity Offering in the amount of £0.3 million.Sep 24genedrive plc Announces the Genedrive MT-RNR1 ID Kit Is Being Introduces by NHS Greater Glasgow and ClydeAug 21Genedrive plc Provides Earnings Guidance for the Year Ending June 30, 2025Aug 13genedrive CYP2C19 ID Kit Receives CE-Certification Under the European in Vitro Diagnostics RegulationMay 30genedrive plc Announces CYP2C19 ID Kit CE-IVD Certification UpdateMay 05genedrive plc has completed a Follow-on Equity Offering in the amount of £0.226309 million.Apr 01genedrive plc has filed a Follow-on Equity Offering.Mar 28genedrive plc has filed a Follow-on Equity Offering in the amount of £1 million.Mar 27genedrive plc, Annual General Meeting, Dec 30, 2024Dec 07genedrive plc to Report Fiscal Year 2024 Results on Nov 29, 2024Nov 22genedrive plc Announces Successful Funding Award to Its Clinical Partners from the National Institute for Health and Care Research in Collaboration with the UK Government Office for Life SciencesNov 21New minor risk - Financial data availability Oct 14Genedrive plc Announces CEO ChangesAug 06Genedrive plc Receives Breakthrough Device Designation from the U.S. Food and Drug AdministrationJul 15genedrive plc has completed a Follow-on Equity Offering in the amount of £6 million.May 31genedrive plc has filed a Follow-on Equity Offering in the amount of £3.5 million.May 11New major risk - Shareholder dilution Apr 06genedrive plc to Report First Half, 2024 Results on Mar 28, 2024Mar 16New major risk - Market cap size Feb 07genedrive plc, Annual General Meeting, Dec 29, 2023Dec 07Full year 2023 earnings released: UK£0.055 loss per share (vs UK£0.055 loss in FY 2022) Dec 01New major risk - Market cap size Nov 21genedrive plc to Report Fiscal Year 2023 Results on Nov 30, 2023Nov 17New minor risk - Financial data availability Oct 18genedrive plc Announces Chief Executive Officer ChangesSep 12Genedrive plc Achieves UKCA Marking Registration for its New Genedrive CYP2C19 SystemSep 06genedrive plc, Annual General Meeting, Dec 29, 2022Dec 06Full year 2022 earnings released: UK£0.055 loss per share (vs UK£0.012 loss in FY 2021) Nov 22genedrive plc to Report Fiscal Year 2022 Results on Nov 21, 2022Nov 14genedrive plc Files US FDA Pre-Submission for the Genedrive® MT-RNR1 Product RangeOct 06Genedrive plc Announces UK's National Institute for Health and Clinical Excellence Commences an Evaluation of CYP2C19 Genotype Testing for Clopidogrel TreatmentAug 22NICE to Evaluate the Genedrive MT-RNR1 TestJun 16High number of new directors May 31Genedrive plc Announces Point-Of-Care Cov19-Id Kit Receives CTDA Approval from Medicines and Healthcare Products Regulatory AgencyMay 31High number of new directors Apr 27Now 24% undervalued Apr 06First half 2022 earnings released Mar 30Genedrive plc Announces NICE issues Medtech Innovation Briefing on Genedrive ® MT-RNR1 TestMar 30genedrive plc Announces Resignation of Matthew Fowler as Group's Chief Financial OfficerMar 03Genedrive plc Provides Update on Point of Care Covid TestFeb 24genedrive plc to Report First Half, 2022 Results on Mar 29, 2022Feb 04genedrive plc Announces UK CTDA application for Point-of-Care Genedrive®?COV19-ID kitDec 23Full year 2021 earnings released: UK£0.012 loss per share (vs UK£0.55 loss in FY 2020) Nov 10Insufficient new directors Sep 02Genedrive COVID-19 Point of Care device updateJul 02First half 2021 earnings released: EPS UK£0.019 (vs UK£0.089 loss in 1H 2020) Mar 28genedrive plc Enters Distribution Agreement with Mountain Horse SolutionsMar 09genedrive plc Provides an Update on its Antibiotic Induced Hearing Loss AssayMar 04New 90-day high: €1.05 Feb 07genedrive plc Enters into Distribution Agreement with Beckman Coulter Life SciencesJan 29genedrive plc to Report First Half, 2021 Results on Mar 25, 2021Jan 19New 90-day low: €0.32 Jan 14genedrive plc, Annual General Meeting, Dec 30, 2020Jan 01New 90-day low: €0.37 Dec 12Genedrive plc Announces Successful Completion of the Antibiotic Induced Hearing Loss Implementation StudyDec 04Revenue misses expectations Nov 30Full year 2020 earnings released: UK£0.55 loss per share Nov 30Genedrive Announces HCV ID Kit Demonstrates High Clinical Accuracy in India StudyNov 20Full year 2020 earnings released: UK£0.55 loss per share Nov 19Revenue misses expectations Nov 19New 90-day low: €0.71 Nov 09genedrive plc to Report Fiscal Year 2020 Results on Nov 17, 2020Oct 29genedrive plc Announces South African ApprovalOct 04genedrive plc Announces Completes Initial Testing of Beckman Coulter Life Sciences' Rnadvance Viral RNASep 26New 90-day high: €1.48 Sep 22決済の安定と成長配当データの取得安定した配当: D6Mの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: D6Mの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場genedrive 配当利回り対市場D6M 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (D6M)n/a市場下位25% (DE)1.6%市場トップ25% (DE)4.5%業界平均 (Life Sciences)0.9%アナリスト予想 (D6M) (最長3年)n/a注目すべき配当: D6Mは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: D6Mは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: D6Mの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: D6Mが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/04 16:37終値2026/04/30 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋genedrive plc 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Mark BrewerCavendishJohn SavinEdison Investment ResearchNigel Bligh HawkinsHardman & Co.2 その他のアナリストを表示
genedrive plc has completed a Follow-on Equity Offering in the amount of £0.5 million.Feb 14+ 2 more updates
genedrive plc Announces Pilot Programme Study Results Underpinning Nhs Implementation Guide for Cyp2c19 Genotype Testing Presented At the Uk Stroke ForumDec 02
genedrive plc has completed a Follow-on Equity Offering in the amount of £3.1975 million.Sep 25+ 1 more update
genedrive plc Announces the Genedrive MT-RNR1 ID Kit Is Being Introduces by NHS Greater Glasgow and ClydeAug 21
genedrive CYP2C19 ID Kit Receives CE-Certification Under the European in Vitro Diagnostics RegulationMay 30
genedrive plc Announces Successful Funding Award to Its Clinical Partners from the National Institute for Health and Care Research in Collaboration with the UK Government Office for Life SciencesNov 21
Genedrive plc Receives Breakthrough Device Designation from the U.S. Food and Drug AdministrationJul 15
Genedrive plc Announces UK's National Institute for Health and Clinical Excellence Commences an Evaluation of CYP2C19 Genotype Testing for Clopidogrel TreatmentAug 22
Genedrive plc Announces Point-Of-Care Cov19-Id Kit Receives CTDA Approval from Medicines and Healthcare Products Regulatory AgencyMay 31
Genedrive plc Announces Successful Completion of the Antibiotic Induced Hearing Loss Implementation StudyDec 04
genedrive plc Announces Completes Initial Testing of Beckman Coulter Life Sciences' Rnadvance Viral RNASep 26